|
NAA50 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.9150000003273E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.71184999999685E-05 |
| Normal-vs-Stage2 |
2.568300E-04 |
| Normal-vs-Stage3 |
5.77789999955947E-07 |
| Normal-vs-Stage4 |
3.61680000005027E-06 |
| Stage1-vs-Stage2 |
6.872800E-01 |
| Stage1-vs-Stage3 |
2.711200E-01 |
| Stage1-vs-Stage4 |
2.828800E-01 |
| Stage2-vs-Stage3 |
7.111600E-01 |
| Stage2-vs-Stage4 |
6.077000E-01 |
| Stage3-vs-Stage4 |
8.155800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.73820000004543E-06 |
| Normal-vs-AfricanAmerican |
3.458500E-02 |
| Normal-vs-Asian |
4.37189999999976E-05 |
| Caucasian-vs-AfricanAmerican |
3.059200E-01 |
| Caucasian-vs-Asian |
6.864600E-01 |
| AfricanAmerican-vs-Asian |
2.233400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.58649999979244E-07 |
| Normal-vs-Female |
2.36430000000176E-06 |
| Male-vs-Female |
1.700840E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.987900E-04 |
| Normal-vs-Age(41-60Yrs) |
3.44560000531402E-08 |
| Normal-vs-Age(61-80Yrs) |
3.66409999996709E-06 |
| Normal-vs-Age(81-100Yrs) |
6.331900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.524500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.636600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.528400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.153600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.850200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.048400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.276600E-01 |
| Classical-VS-Follicular |
4.001600E-04 |
| Classical-VS-Other |
5.101900E-02 |
| Classical-VS-Normal |
8.45280000000281E-05 |
| Tall-VS-Follicular |
1.484610E-01 |
| Tall-VS-Other |
1.251650E-01 |
| Tall-VS-Normal |
1.520780E-03 |
| Follicular-VS-Other |
5.097000E-01 |
| Follicular-VS-Normal |
4.90070000136456E-08 |
| Other-VS-Normal |
7.836600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.2993999998212E-07 |
| Normal-vs-N1 |
4.45459999998121E-07 |
| N0-vs-N1 |
2.699600E-01 |
|
|
